scholarly journals Calculation of Absorption Dose Value using MIRD Method with Cobalt 57 MIBI for Four Body Organs

2019 ◽  
Vol 2 (1) ◽  
pp. 72
Author(s):  
Asep Yoyo Wardaya ◽  
Wahyu Setia Budi ◽  
Ali Khumaeni ◽  
Chorirul Anam ◽  
Gani Gunawan
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
The Body ◽  
Radiation Doses ◽  
Breast Cancer Patients ◽  
Internal Radiation ◽  
Cumulative Activity ◽  
S Factor ◽  
Time Variations

MIRD has developed methods, assumptions, models, and mathematical formulae for estimating internal radiation doses from the injected radiopharmaceuticals into the body. This study aims to determine the radiopharmaceutical distribution of Cobalt 57 MIBI in patients identified as having breast cancer by using an oncology examination with MIRD method on 4 patient's organs with some time variations. The four organs of the patient's body are the heart, thyroid, kidney, and liver. The MIRD method developed to calculate the absorption dose of each organ is the product of the cumulative activity and the S factor of each organ studied. The results showed that the highest uptake dose in these patients was in the thyroid and kidney organs, and then followed by the heart and liver. These results indicate that the thyroid and kidney organs are the most vulnerable organs by the method of injecting radiopharmaceutical doses into the body of breast cancer patients.

scholarly journals CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Jennifer K. Lang ◽  
Badri Karthikeyan ◽  
Adolfo Quiñones-Lombraña ◽  
Rachael Hageman Blair ◽  
Amy P. Early ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Care Center ◽  
Left Ventricular ◽  
The Body ◽  
Left Ventricular Ejection ◽  
Breast Cancer Patients ◽  
Ventricular Ejection Fraction ◽  
Echocardiographic Parameters ◽  
The Impact

Abstract Background The CBR3 V244M single nucleotide polymorphism has been linked to the risk of anthracycline-related cardiomyopathy in survivors of childhood cancer. There have been limited prospective studies examining the impact of CBR3 V244M on the risk for anthracycline-related cardiotoxicity in adult cohorts. Objectives This study evaluated the presence of associations between CBR3 V244M genotype status and changes in echocardiographic parameters in breast cancer patients undergoing doxorubicin treatment. Methods We recruited 155 patients with breast cancer receiving treatment with doxorubicin (DOX) at Roswell Park Comprehensive Care Center (Buffalo, NY) to a prospective single arm observational pharmacogenetic study. Patients were genotyped for the CBR3 V244M variant. 92 patients received an echocardiogram at baseline (t0 month) and at 6 months (t6 months) of follow up after DOX treatment. Apical two-chamber and four-chamber echocardiographic images were used to calculate volumes and left ventricular ejection fraction (LVEF) using Simpson’s biplane rule by investigators blinded to all patient data. Volumetric indices were evaluated by normalizing the cardiac volumes to the body surface area (BSA). Results Breast cancer patients with CBR3 GG and AG genotypes both experienced a statistically significant reduction in LVEF at 6 months following initiation of DOX treatment for breast cancer compared with their pre-DOX baseline study. Patients homozygous for the CBR3 V244M G allele (CBR3 V244) exhibited a further statistically significant decrease in LVEF at 6 months following DOX therapy in comparison with patients with heterozygous AG genotype. We found no differences in age, pre-existing cardiac diseases associated with myocardial injury, cumulative DOX dose, or concurrent use of cardioprotective medication between CBR3 genotype groups. Conclusions CBR3 V244M genotype status is associated with changes in echocardiographic parameters suggestive of early anthracycline-related cardiomyopathy in subjects undergoing chemotherapy for breast cancer.

scholarly journals Dose Distribution in the Heart and Cardiac Chambers following 4-field Radiation Therapy of Breast Cancer: a Retrospective Study

2013 ◽  
Vol 7 ◽  
pp. BCBCR.S11118 ◽  
Author(s):  
Safora Johansen ◽  
Kristin H. Tjessem ◽  
Kristian Fosså ◽  
Gerhard Bosse ◽  
Turi Danielsen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Normal Tissue Complication Probability ◽  
Radiation Doses ◽  
Breast Cancer Patients ◽  
Heart Volume ◽  
Volume Percentage ◽  
Dose Volume Histograms ◽  
Field Radiation ◽  
Whole Heart

Purpose To evaluate cardiac doses in breast cancer patients with stage II/III treated with 4-field radiotherapy based on computed tomography (CT) dose planning. Methods and Materials Based on archived CT images, whole heart and cardiac chamber radiation doses were analyzed in 216 (111 left-sided and 105 right-sided) mastectomized or lumpectomized breast cancer patients treated at a single institution, the Norwegian Radium Hospital, between 2000–2002. Individual dose volume histograms for the whole heart and for the four cardiac chambers were obtained, and mean, median and maximum doses to these structures were calculated. The dose (Gy) delivered to the 5% of the volume of each cardiac structure (D5%), and the volume percentage of each structure receiving ≥ 25 Gy (V25Gy) were reported. Normal tissue complication probability (NTCP) calculations were used to estimate the risk for ischemic heart disease (IHD). Results Cohort-based medians of the whole heart mean dose (Dmean) for left- and right-sided tumors were 3.2 Gy and 1.3 Gy, respectively, with similar ventricular but lower atrial values. The atrial doses did not differ according to laterality of the breast tumor. In 13 patients with left-sided cancer, 5% of the heart volume was exposed to >25 Gy. The NTCP estimates were generelly low, with a maximum of 2.8%. Conclusions During adjuvant CT-based locoregional radiotherapy of women with breast cancer, the cardiac radiation doses are, at the group level, below recommended threshold values (D5% < 25 Gy), though individual patients with left-sided disease may exceed these limits.

scholarly journals Analysis of the Effect of Prognosis Factors for Breast Cancer

2020 ◽  
Author(s):  
Mrinal Deka ◽  
Dibyojyoti Bhattacharjee
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Cancer Patients ◽  
Tumour Size ◽  
Poverty Line ◽  
The Body ◽  
Research Centre ◽  
Breast Cancer Patients ◽  
Prognosis Factor ◽  
Regional Lymph Nodes

Abstract Background: The idea of Prognosis factor is based on the variables that can be used to assess the chance of recovery from a disease. It is also considered as the prior knowledge about any disease before treatment. The concept is applied to the cancer patients to get an idea of how cancer will affect the body and how it will respond to the therapies. Method: In this paper, selective prognostic factors (Age, Node and Tumour size) are analysed by logistic regression in patients who are suffering from Breast cancer based on data collected from Cachar Cancer Hospital and Research Centre, Silchar, Assam, India. Results: The study claims that there are 50.1 percent and 65.8 percent chance of remission of cancer for patients of age above 50 in case of breast cancer with below poverty line and above poverty line respectively. The present study has focused on this cut-off value of 2 cm as the determining prognostic factor in relation to tumour size. Thus, the chance of remission from cancer is 22.3 percent and 34.7 percent for below poverty line and above poverty line patients respectively, if tumour size is greater than 2 cm.It also endeavours to ascertain that there are 10.9 percent and 18.1 percent chances of remission of cancer, if the disease has metastasized to regional lymph nodes, with below poverty line and above poverty line respectively.Conclusion: The parameters viz. Tumour size and Node status, which measure the stage of the cancer patients, are significant prognostic factors that help in predicting tumour behaviour and survival outcomes for breast cancer patients.

scholarly journals The Association of Serum IL-33 and sST2 with Breast Cancer

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Zhi-Ping Yang ◽  
Dan-Yan Ling ◽  
Yong-Hong Xie ◽  
Wan-Xin Wu ◽  
Jin-Rui Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Healthy Volunteers ◽  
Cancer Patients ◽  
Serum Levels ◽  
The Body ◽  
Breast Cancer Dataset ◽  
Breast Cancer Patients ◽  
Interleukin 33 ◽  
Factor C

Breast cancer is one of the most common malignant diseases in women. The main cause of death from breast cancer is its metastases at distant sites in the body. Interleukin-33 (IL-33) is a cytokine of the IL-1 family and found overexpressed in various cancers. The aim of the present study was to explore the association of serum IL-33 and sST2 with breast cancer. Here, the serum levels of Interleukin-33 (IL-33) and sST2 were found significantly higher in breast cancer patients than in healthy volunteers. Serum levels of vascular endothelial growth factor (VEGF), metalloproteinase-11 (MMP-11), and platelet-derived growth factor-C (PDGF-C) were also greater in breast cancer patients compared to healthy volunteers. We found that serum levels of IL-33 or sST2 were positively correlated with the serum levels of VEGF, MMP-11, and PDGF-C. Moreover, breast cancer dataset downloaded from The Cancer Genome Atlas showed that patients with higher level of MMP-11 or PDGF-C expression had shorter survival time than those with lower level of these proteins. In conclusion, IL-33 and sST2 may serve as noninvasive diagnosis markers for breast cancer. IL-33 and sST2 were significantly associated with MMP-11 or PDGF-C which indicated poor prognosis of breast cancer patients.

scholarly journals Impact of BMI for clinical outcomes in Japanese breast cancer patients

2020 ◽  
Vol 50 (3) ◽  
pp. 230-240
Author(s):  
Naomi Gondo ◽  
Masataka Sawaki ◽  
Masaya Hattori ◽  
Akiyo Yoshimura ◽  
Haruru Kotani ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Clinical Outcomes ◽  
Disease Free Survival ◽  
Overweight And Obesity ◽  
The Body ◽  
Breast Cancer Patients ◽  
Cancer Specific Survival ◽  
Er Positive ◽  
The Impact

Abstract Objective The relationship between the body mass index (BMI) at the time of breast cancer diagnosis and the prognosis of breast cancer patients has not yet been clarified. We investigated the impact of obesity for clinical outcomes in Japanese breast cancer patients. Methods Women with primary breast cancer operated between 2002 and 2014 were identified. All patients are categorized into four groups according to BMI. The range of BMI is &lt;18.5 kg/m2, from 18.5 to 24.9 kg/m2, 25 to 29.9 kg/m2, &gt;30 kg/m2 in underweight, normal, overweight and obesity groups, respectively. The correlation between BMI and overall survival (OS), breast cancer-specific survival (BCSS) and disease-free survival (DFS) were statistically analyzed. Results From the database of our institution, we identified 3223 patients. The median follow-up period was 57 months (1–149). We categorized 2257 (70.0%), 318 (9.9%), 545 (16.9%) and 103 (3.2%) patients into normal, underweight, overweight obesity groups respectively. There were189 patients (5.9%) deaths due to breast cancer recurrence (137 patients) and other disease (52 patients). Obesity groups was significantly high compared with normal groups for OS (adjusted HR, 2.43; 95% CI, 1.38–4.28; P &lt; 0.001), BCSS (adjusted HR, 2.73; 95% CI, 1.15–6.44; P = 0.02) and DFS (adjusted HR, 1.83; 95% CI, 1.11–3.02; P = 0.017) by multivariate analysis. Especially, OS (adjusted HR, 4.87; 95% CI, 2.15–11.04; P &lt; 0.001), BCSS (adjusted HR, 4.51; 95% CI, 1.52–13.34; P &lt; 0.001) and DFS (adjusted HR, 4.87; 95% CI, 1.02–4.89; P = 0.04) were statistically insignificant in postmenopausal ER-positive breast cancer patients. Conclusion Obesity might be risk factor for OS, BCSS and DFS, especially postmenopausal ER-positive women.

scholarly journals 8-Hydroxy-2’-Deoxyguanosine and 8-Nitroguanine Production and Detection in Blood Serum of Breast Cancer Patients in Response to Postoperative Complementary External Ionizing Irradiation of Normal Tissues

Dose-Response ◽  
2020 ◽  
Vol 18 (4) ◽  
pp. 155932582098217
Author(s):  
Kosmas E. Verigos ◽  
Sofia Sagredou ◽  
Kyriakos Orfanakos ◽  
Panayiotis Dalezis ◽  
Dimitrios T. Trafalis
Keyword(s):  
Breast Cancer ◽  
Radiation Dose ◽  
Blood Serum ◽  
Cancer Patients ◽  
Polynomial Regression ◽  
Research Work ◽  
Enzyme Linked Immunosorbent Assay ◽  
Radiation Doses ◽  
Breast Cancer Patients ◽  
Ionizing Irradiation

It is widely known that ionizing irradiation is strongly linked to the production of reactive oxygen (ROS) and nitrative species (RNS) through which DNA damage products like 8-hydroxy-2-deoxyguanosine (8-OHdG) and 8-nitroguanine (8-NG) are generated, respectively. In the present study, we aimed to investigate the formation of 8-OHdG and 8-NG upon irradiation and to further explore whether alterations in their concentration levels are related to the administered radiation doses and exposure time. Our research work was conducted in blood serum samples collected from 33 breast cancer patients who received adjuvant radiotherapy. The detection of 8-OHdG and 8-NG was assessed by enzyme-linked immunosorbent assay. Our results suggest that both, 8-OHdG and 8-NG, were formed during the radiation regimen. Significant correlations with radiation dose were also demonstrated by the dose-response curves of 8-OHdG and 8-NG, fitted by logarithmic distribution and polynomial regression, respectively. More precisely, 8-OHdG and 8-NG concentrations (ng/mL) were considerably increased when patients received ionizing radiation up to 30 Gy whereas irradiation over 30 Gy did not induce any further increases. The current study supports a) the production of 8-OHdG and 8-NG during radiotherapy and b) significant correlations between either 8-OHdG or 8-NG levels and radiation doses, indicating a radiation-dose-dependent relationship.

Sign in / Sign up

Export Citation Format

Share Document